Iamotrigine monotherapy overpowers carbamazepine in post stroke epilepsy
Patients with Poststroke Epilepsy receiving lamotrigine monotherapy had significantly lower mortality compared with those receiving carbamazepine, according to a recent study published in the JAMA Neurology.
There is little evidence to guide the choice of antiseizure medication (ASM) for patients with poststroke epilepsy. Theoretical concerns about the detrimental effects of ASMs on survival exist. Enzyme-inducing drugs could interfere with secondary stroke prevention. The US Food and Drug Administration recently issued a safety announcement about the potential proarrhythmic properties of lamotrigine. A group of researchers conducted a study to investigate whether mortality varies with specific ASMs among patients with poststroke epilepsy.
For more information check out the link below:
lamotrigine monotherapy better than carbamazepine in Poststroke Epilepsy: JAMA
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd